Home / Therapeutic Area / Pneumonia Drug Development Pipeline Review, 2017

Pneumonia Drug Development Pipeline Review, 2017

Published: Sep 2017 | Published By: GBI Research

Description

This report provides an overview of the pipeline landscape for pneumonia disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and Ventilator Associated Pneumonia and features dormant and discontinued projects.

Community acquired pneumonia is pneumonia contracted by a person who has had little contact with the healthcare system, with common symptoms including cough, fever and shortness of breath. Risk factors include chronic lung disease, cigarette smoking, immune system problems and surgery.

Hospital acquired pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48-72 hours after being admitted. Signs and symptoms include malaise, fever, chills, rigor, cough, dyspnea, and chest pain, but in ventilated patients, pneumonia usually manifests as worsening oxygenation and increased tracheal secretions.

Finally, ventilator associated pneumonia is pneumonia that occurs in people who are on mechanical ventilation breathing machines in hospitals. As such the disease typically affects critically ill patients and increases the risk of mortality. Signs and symptoms include fever or low body temperature, new purulent sputum and hypoxemia.

The size of these pipelines ranges from 20 products in community acquired pneumonia to 39 in hospital acquired pneumonia. Across all three of these indications bacterial targets such as DNA gyrase and ribosomal DNA are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope

  • Which companies are the most active within the pipeline for pneumonia therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of pneumonia?

Reasons To Buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Executive Summary

3 Introduction
3.1 Pneumonia Report Coverage
3.2 Community Acquired Pneumonia – Overview
3.3 Hospital Acquired Pneumonia (HAP) – Overview
3.4 Ventilator Associated Pneumonia (VAP) – Overview
3.5 GBI Research Report Guidance

4 Therapeutics Development
4.1 Community Acquired Pneumonia
4.1.1 Pipeline Overview
4.1.2 Pipeline by Companies
4.1.3 Products under Development by Companies
4.2 Hospital Acquired Pneumonia (HAP)
4.2.1 Pipeline Overview
4.2.2 Pipeline by Companies
4.2.3 Products under Development by Companies
4.3 Ventilator Associated Pneumonia (VAP)
4.3.1 Pipeline Overview
4.3.2 Pipeline by Companies
4.3.3 Products under Development by Companies

5 Therapeutics Assessment
5.1 Community Acquired Pneumonia
5.1.1 Assessment by Target
5.1.2 Assessment by Mechanism of Action
5.1.3 Assessment by Route of Administration
5.1.4 Assessment by Molecule Type
5.2 Hospital Acquired Pneumonia (HAP)
5.2.1 Assessment by Target
5.2.2 Assessment by Mechanism of Action
5.2.3 Assessment by Route of Administration
5.2.4 Assessment by Molecule Type
5.3 Ventilator Associated Pneumonia (VAP)
5.3.1 Assessment by Target
5.3.2 Assessment by Mechanism of Action
5.3.3 Assessment by Route of Administration
5.3.4 Assessment by Molecule Type

6 Companies Involved in Therapeutics Development
6.1 Community Acquired Pneumonia
6.1.1 Aridis Pharmaceuticals LLC6.1.2 Biotest AG
6.1.3 InflaRx GmbH
6.1.4 ioGenetics Inc
6.1.5 Kyorin Pharmaceutical Co Ltd
6.1.6 Melinta Therapeutics Inc
6.1.7 Merck & Co Inc
6.1.8 Nabriva Therapeutics AG
6.1.9 Paratek Pharmaceuticals Inc
6.1.10 TaiGen Biotechnology Co Ltd
6.1.11 Takeda Pharmaceutical Company Ltd
6.1.12 Tetraphase Pharmaceuticals Inc
6.1.13 TiGenix NV
6.1.14 Wockhardt Ltd
6.2 Hospital Acquired Pneumonia (HAP)
6.2.1 Achaogen Inc
6.2.2 Adenium Biotech ApS
6.2.3 Aridis Pharmaceuticals LLC
6.2.4 AstraZeneca Plc
6.2.5 Bayer AG
6.2.6 Cardeas Pharma Corp
6.2.7 Destiny Pharma Ltd
6.2.8 Dong-A Socio Holdings Co Ltd
6.2.9 Lakewood-Amedex Inc
6.2.10 MedImmune LLC
6.2.11 Meiji Seika Pharma Co Ltd
6.2.12 Melinta Therapeutics Inc
6.2.13 Merck & Co Inc
6.2.14 Motif Bio Plc
6.2.15 Nabriva Therapeutics AG
6.2.16 Polyphor Ltd
6.2.17 Sealife PHARMA GMBH
6.2.18 Shionogi & Co Ltd
6.2.19 Tetraphase Pharmaceuticals Inc
6.2.20 The Medicines Company
6.2.21 Theravance Biopharma Inc
6.2.22 Wockhardt Ltd
6.2.23 Zavante Therapeutics Inc
6.3 Ventilator Associated Pneumonia (VAP)
6.3.1 Achaogen Inc
6.3.2 Adenium Biotech ApS
6.3.3 Aridis Pharmaceuticals LLC
6.3.4 AstraZeneca Plc
6.3.5 Bayer AG
6.3.6 Cardeas Pharma Corp
6.3.7 Destiny Pharma Ltd
6.3.8 Dong-A Socio Holdings Co Ltd
6.3.9 Lakewood-Amedex Inc
6.3.10 MedImmune LLC
6.3.11 Meiji Seika Pharma Co Ltd
6.3.12 Merck & Co Inc
6.3.13 Motif Bio Plc
6.3.14 Nabriva Therapeutics AG
6.3.15 Polyphor Ltd
6.3.16 Shionogi & Co Ltd
6.3.17 Tetraphase Pharmaceuticals Inc
6.3.18 The Medicines Company
6.3.19 Theravance Biopharma Inc
6.3.20 Wockhardt Ltd
6.3.21 Zavante Therapeutics Inc

7 Dormant Projects
7.1 Community Acquired Pneumonia
7.2 Hospital Acquired Pneumonia (HAP)
7.3 Ventilator Associated Pneumonia (VAP)

8 Discontinued Products
8.1 Community Acquired Pneumonia
8.2 Hospital Acquired Pneumonia (HAP)
8.3 Ventilator Associated Pneumonia (VAP)

9 Product Development Milestones
9.1 Community Acquired Pneumonia
9.1.1 Featured News & Press Releases
9.2 Hospital Acquired Pneumonia (HAP)
9.2.1 Featured News & Press Releases
9.3 Ventilator Associated Pneumonia (VAP)
9.3.1 Featured News & Press Releases

10 Appendix
10.1 Methodology
10.2 Coverage
10.3 Secondary Research
10.4 Primary Research
10.5 Expert Panel Validation
10.6 Contact Us
10.7 Disclaimer

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +